Compare Ecopetrol SA (EC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Viatris Inc — how do they compare? Ecopetrol SA trades at $15.99 (market cap $30.44B), while Viatris Inc trades at $17.19 (market cap $19.44B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays the higher dividend (4.06%). Which is the better fit depends on your goals.
| EC | VTRS | |
|---|---|---|
Market Cap | $30.44B | $19.44B |
Sector | Energy | Health |
52-Week High | $16.58 | $17.39 |
52-Week Low | $8.29 | $8.74 |
Enterprise Value | $58.23B | $31.65B |
Dividend Yield | 4.06% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.16, up 1.76% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company maintains solid profitability with an 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6T in 2022 to $119.7T in 2025. Recent developments include a finalized labor agreement with the USO union and S&P affirming its BB- credit rating with a stable outlook on June 17, 2026.
The stock presents a mixed outlook: valuation appears reasonable with a P/E of 11.39, but earnings misses and declining revenue pose risks. Analyst consensus is cautious with a $14.63 price target below current levels. Key opportunities include stable cash flow and dividend payments, while risks involve oil price volatility and execution challenges in a competitive energy sector.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
